Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03543826 · ClinicalTrials.gov registry record · Phase 4

Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex

A Phase 4 study of Muscle Weakness, sponsored by University of Washington.

Completed
Registry status
Phase 4
Development phase
201
Enrollment target
1
Study location

NCT03543826 is a Phase 4 study of Muscle Weakness that has completed, run by University of Washington. The registered enrollment target is 201 participants, above the 67-participant average among 25 other Muscle Weakness trials with a reported enrollment target (200% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03543826, a Phase 4 study of Muscle Weakness, has completed, sponsored by University of Washington.

COMPLETED
Registry status
Phase 4
Development phase
201 participants
Enrollment target
1
Study location

Study Summary

This is an estimation study, prospectively evaluating the incidence of postoperative residual neuromuscular blockade (PRNB) when a best practice protocol is implemented for a cohort of abdominal surgery and orthopedic surgery patients. The protocol is developed within the constraint of subjective monitoring, quantitative monitoring is not used, and use of rocuronium for paralysis and either neostigmine or sugammadex for reversal. The primary outcome is the incidence of PRNB on arrival to the post-anesthesia care unit, defined as a train-of-four ration \<0.9.

Conditions Studied

Muscle Weakness

Interventions

  • COMBINATION_PRODUCT Protocol for rocuronium neuromuscular block

Study Locations (1)

Washington

  • University of Washington Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 201 participants
Start Date 2018-05-21
Est. Completion 2018-11-26
Phase Phase 4

Sponsor

University of Washington

1,048 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03543826

The ClinicalTrials.gov registry entry for NCT03543826 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 25 other Muscle Weakness trials with a reported enrollment target (200% higher). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Muscle Weakness appearing as the primary indexed condition, and to 1 intervention - of which Protocol for rocuronium neuromuscular block is the first listed.

NCT03543826 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT03543826 about?

NCT03543826 is a clinical study titled "Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex". This is an estimation study, prospectively evaluating the incidence of postoperative residual neuromuscular blockade (PRNB) when a best practice protocol is implemented for a cohort of abdominal surgery and orthopedic surgery patients. The protocol is developed within the constraint of subjective mo...

What is the current status of trial NCT03543826?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 201 participants. The study started on 2018-05-21. Estimated completion is 2018-11-26.

What conditions does trial NCT03543826 study?

This clinical trial studies the following conditions: Muscle Weakness.

What interventions are being tested in trial NCT03543826?

The interventions under investigation include: Protocol for rocuronium neuromuscular block (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT03543826?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03543826 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Muscle Weakness

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Muscle Weakness

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.